GSK Spins Out Pain Assets, Raises $35.4m
This article was originally published in The Pink Sheet Daily
Executive Summary
UK-based Convergence's lead asset starts Phase II in neuropathic pain
You may also be interested in...
NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.